<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463515</url>
  </required_header>
  <id_info>
    <org_study_id>CHER@NOS</org_study_id>
    <nct_id>NCT00463515</nct_id>
  </id_info>
  <brief_title>Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC</brief_title>
  <acronym>CHER@NOS</acronym>
  <official_title>A Multicenter Phase II Study of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation in Patients With Non-resectable Stage III Non-Small-Cell-Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based
      induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is
      possible to obtain optimal efficacy with minimal toxicity. Patients will be treated with 3
      cycles of induction chemotherapy, unless there is the occurrence of early intrathoracic
      progression of disease. The induction chemotherapy is then to be followed by
      chemo-radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year survival rates</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intrathoracic failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of induction chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of chemo-radiotherapy</measure>
  </secondary_outcome>
  <enrollment>77</enrollment>
  <condition>Non-Small-Cell-Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin/gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cisplatin/radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cytological or histologically proven NSCLC

          -  unresectable stage III NSCLC

          -  presence of at least one measurable lesion (RECIST criteria)

          -  adequate haematological, renal and hepatic function

          -  adequate lung function reserve

          -  good condition, weight loss &lt;10% over previous 6 months, life expectancy &gt; 3 months

        Exclusion Criteria:

          -  previous chemotherapy for NSCLC

          -  distant metastasis or a pleural or pericardial effusion

          -  treatment for malignant disease in the past or serious concomitant medical or
             psychiatric disease

          -  active uncontrolled infection at time of inclusion

          -  interstitial lung disease

          -  auto-immune systemic disease with potential involvement of the lungs

          -  concomitant use of amiodarone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul R Germonpre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Augustinus Ziekenhuis</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>lung cancer</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>chemo-radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

